March Newsletter: Post-translational Modifications of β-catenin and TFC/LEF-1 Regulate Canonical Wnt Signaling

 Newsletter Thumbnail - Click for PDF Version
View PDF Here

Protein post-translational modifications (PTMs) such as phosphorylation, acetylation, ubiquitination, and SUMOylation, to name but a few, have evolved to diversify the functions of a single protein and account for the vast increase in proteome complexity and functional diversity1. A prime example of the complex and dynamic regulatory power PTMs confer is the Wnt/β-catenin signaling pathway2,3. This pathway regulates cellular proliferation, differentiation, and migration during embryonic development and adult cell homeostasis4-6. In addition, dysregulation of Wnt/β-catenin signaling is implicated in multiple pathological conditions, including carcinogenesis and degenerative diseases5,7. In canonical Wnt-mediated signaling, β-catenin is a key effector and interacts, as a co-transcription factor, with the DNA binding proteins TCF (T cell factor) and LEF-1 (lymphoid enhancer factor 1) to activate the transcription of Wnt/β-catenin target genes including cyclin D1, c-jun, and c-myc8-11 (Fig. 1). In this newsletter, the functional regulation of β-catenin and TCF/LEF-1 by PTMs is discussed.

 Post-Translational Regulation of β-Catenin in Wnt Signaling  

In the absence of Wnt binding to the co-receptor complex of Frizzled (Fz) and low-density lipoprotein receptor-related proteins (LRP) 5 and 6, a multi-protein destruction complex consisting of the scaffolding/tumor suppressor proteins Axin and adenomatous polyposis coli (APC), and the serine/threonine kinases casein kinase 1α (CK-1α) and glycogen synthase kinase 3 (GSK3) mediates phosphorylation of β-catenin2,3,9. Under these quiescent conditions, β-cateinin is sequentially phosphorylated on Ser45 by CK-1α, followed by phosphorylation of Ser33, Ser37, and Thr41 by GSK312 (Fig. 1). Upon phosphorylation, the E3 ubiquitin ligase β-transducin repeats containing protein (β-TrCP) ubiquitinates phospho-β-catenin on Lys19 and Lys4913,14, which leads to proteasomal destruction and low β-catenin levels and activity15,16. Conversely, in the presence of Wnt binding, the scaffold protein Dishevelled (Dvl) is recruited to the Fz-LRP5/6 co-receptor complex, which activates a sequence of molecular signals that inhibit the destruction complex and result in stabilization of unphosphorylated, cytosolic β-catenin and β-catenin-dependent transcription2,3,17-19. Stabilization occurs through partial inhibition of CK-1α and GSK318, inhibition of β-TrCP20, phosphorylation of five highly conserved PPPSP motifs in LRP6's intracellular domain21,22 (Fig.1), and subsequent aggregation of these Wnt signaling proteins. The negative Wnt regulator Axin is inhibited through recrutiment and direct binding to this aggregate complex3,17.

Notably, the same PTMs can inhibit or enhance β-catenin activity, depending on the residue(s) modified. For example, ubiquitination of Lys394 stabilizes β-catenin17. Similarly, phosphorylation of Ser675 by PKA, Ser552 by AKT, and Ser191/605 by JNK2 stabilizes β-catenin23-25 (Fig. 1). Acetyltransferases act on multiple Lys residues and each acetylation modulates the functional role and stability of β-catenin in different ways: acetylation of Lys49 by CBP inhibits β-catenin’s transcription activity26, acetylation of Lys345 by p300 enhances β-catenin interaction with TCF27, and acetylation of Lys19 and Lys49 by PCAF increases β-catenin stability28. Interestingly, tyrosine phosphorylation seems to only enhance β-catenin activity17.

Fig. 1 PTMs regulate the stability of ß-catenin and TCF/LEF-1 and their interaction; (ßBD:ß-catenin binding domain, HMG: High mobility group, ↑: favors interaction,     : inhibits interaction).
Fig. 1 PTMs regulate the stability of ß-catenin and TCF/LEF-1 and their interaction; (ßBD:ß-catenin binding domain, HMG: High mobility group, ↑: favors interaction, ⊥: inhibits interaction).

 Post-Translational Regulation of TCF/LEF-1 in Wnt Signaling 

TCF and LEF-1 form multimeric transcription complexes with cofactors such as CtBP, HBP1, and β-catenin, which function together to either repress or activate gene expression29,30. The binding affinity between TCF/LEF-1 and co-regulators is significantly affected by each protein’s respective PTM status (Fig. 1). TCF is phosphorylated on multiple Thr/Ser residues with opposing functional effects. For instance, phosphorylation of Ser154 on TCF by the TNIK kinase is required for its transcriptional activity3, while phosphorylation of Thr178 and Thr189 by Nemo-like kinase (NLK) inhibits TCF/DNA binding and suppresses its transcriptional activity31. The phosphorylation of TCF by NLK is linked to TCF ubiquitination. LEF-1 is phosphorylated on Thr155 and Ser166 by NLK, which inhibits DNA binding of the TCF/LEF-1/β-catenin complex3. Conversely, phosphorylation of Ser42 and Ser61 by CK-1 enhances β-catenin binding and transactivation32. The E3 ligase NLK-associated Ring Finger Protein (NARF) ubiquitinates TCF/LEF-1 in vitro and in vivo, which leads to TCF/LEF-1 degradation33. Both TCF and LEF-1 undergo SUMOylation by PIASy, but the functional consequences are distinct. SUMOylation of Lys297 on TCF confers enhanced activity34, while  SUMOylation of Lys25 and Lys267 residues on LEF-1 results in loss of activity35.


Like most, if not all, proteins, the Wnt signaling effector β-catenin and its co-transcriptional regulators TCF and LEF-1 are regulated by multiple PTMs, with the same PTM able to both enhance and inhibit activity, depending on which residue(s) are modified. In addition, PTMs can be cooperative or mutually exclusive. To study such complex and diverse functional regulation of cells' proteomes requires sensitive and quantitative reagents. At Cytoskeleton, Inc., the Signal-Seeker kits offer an unparalleled view into how PTMs regulate protein localization and function with the ability to measure tyrosine phosphorylation, ubiquitination, SUMOylation, and acetylation of endogenous proteins.

Related Products & Resources

Signal Seeker™ Kits    

New Signal-Seeker™ Acetyl-Lysine Detection Kit (30 assay) (Cat. # BK163)

New Signal-Seeker™ Acetyl-Lysine Detection Kit (10 assay) (Cat. # BK163-S)

Signal-Seeker™ Phosphotyrosine Detection Kit (30 assay) (Cat. # BK160)

Signal-Seeker™ Phosphotyrosine Detection Kit (10 assay) (Cat. # BK160-S)

Signal-Seeker™ Ubiquitination Detection Kit (30 assay) (Cat. # BK161)

Signal-Seeker™ Ubiquitination Detection Kit (10 assay) (Cat. # BK161-S)

Signal-Seeker™ SUMOylation 2/3 Detection Kit (30 assay) (Cat. # BK162)

Signal-Seeker™ SUMOylation 2/3 Detection Kit (10 assay) (Cat. # BK162-S)

PTM Antibodies, Beads, Etc   

New Acetyl-Lysine Antibody Mouse Monoclonal (7B5A1) (Cat. # AAC02)

New Acetyl-Lysine-HRP Antibody Mouse Monoclonal (19C4B2.1) (Cat. # AAC03-HRP)

Phosphotyrosine Affinity Beads (Cat. # APY03-beads)

Phosphotyrosine-HRP Mouse Monoclonal Antibody 27B10 (Cat. # APY03-HRP)

SUMOylation 2/3 Affinity Beads (Cat. # ASM24-beads)

Ubiquitin Antibody Mouse Monoclonal (Cat. # AUB01)


  1. Prabakaran S. et al. 2012. Post-translational modification: nature's escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 565-583.
  2. Niehrs C. 2012. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13, 767-779.
  3. Gao C. et al. 2014. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Biosci. 4, 13.
  4. Wodarz A. and Nusse R. 1998. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59-88.
  5. Polakis P. 2000. Wnt signaling and cancer. Genes Dev. 14, 1837-1851.
  6. McCrea P.D. and Gottardi C.J. 2016. Beyond beta-catenin: prospects for a larger catenin network in the nucleus. Nat. Rev. Mol. Cell Biol. 17, 55-64.
  7. Nusse R. and Clevers H. 2017. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 169, 985-999.
  8. MacDonald B.T. et al. 2009. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell. 17, 9-26.
  9. Cong F. et al. 2004. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development. 131, 5103-5115.
  10. Li V.S. et al. 2012. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell. 149, 1245-1256.
  11. Ziegler S. et al. 2005. Novel target genes of the Wnt pathway and statistical insights into Wnt target promoter regulation. FEBS J. 272, 1600-1615.
  12. Liu C. et al. 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108, 837-847.
  13. Wu G. et al. 2003. Structure of a β-TrCP1-Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCF βTrCP1 ubiquitin ligase. Mol. Cell. 11, 1445-1456.
  14. Winer I.S. et al. 2006. Lysine residues Lys-19 and Lys-49 of β-catenin regulate its levels and function in T cell factor transcriptional activation and neoplastic transformation. J. Biol. Chem. 281, 26181-26187.
  15. Aberle H. et al. 1997. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804.
  16. Hart M. et al. 1999. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9, 207-210.
  17. Valenta T. et al. 2012. The many faces and functions of beta-catenin. EMBO J. 31, 2714-2736.
  18. Hernandez A.R. et al. 2012. Kinetic responses of beta-catenin specify the sites of Wnt control. Science. 338, 1337-1340.
  19. Kim S.E. et al. 2013. Wnt stabilization of beta-catenin reveals principles for morphogen receptor-scaffold assemblies. Science. 340, 867-870.
  20. Li V.S.W. et al. 2012. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 149, 1245-1256.
  21. MacDonald B.T. et al. 2008. Wnt signal amplification via activity, cooperativity, and regulation of multiple intracellular PPPSP motifs in the Wnt co-receptor LRP6. J. Biol. Chem. 283, 16115-16123.
  22. Niehrs C. and Shen J. 2010. Regulation of Lrp6 phosphorylation. Cell Mol. Life Sci. 67, 2551-2562.
  23. Hino S. et al. 2005. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell Biol. 25, 9063-9072.
  24. Fang D. et al. 2007. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 282, 11221-11229.
  25. Wu X. et al. 2008. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 133, 340-353.
  26. Wolf D. et al. 2002. Acetylation of beta-catenin by CREB-binding protein (CBP). J. Biol. Chem. 277, 25562-25567.
  27. Levy L. et al. 2004. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol. Cell Biol. 24, 3404-3414.
  28. Ge X. et al. 2009. PCAF acetylates {beta}-catenin and improves its stability. Mol. Biol. Cell. 20, 419-427.
  29. Cadigan K.M. and Waterman M.L. 2012. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb. Perspect. Biol. 4, a007906.
  30. Hurlstone A. and Clevers H. 2002. T-cell factors: turn-ons and turn-offs. EMBO J. 21, 2303-2311.
  31. Ishitani T. et al. 1999. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature. 399, 798-802.
  32. S. Wang S. and Jones K.A. 2006. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr. Biol. 16, 2239-2244.
  33. Yamada M. et al. 2006. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF). J. Biol. Chem. 281, 20749-20760.
  34. Yamamoto H. et al. 2003. Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J. 22, 2047-2059.
  35. Sachdev S. et al. 2001. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15, 3088-3103.
        Shi Y. et al. 2012. PTEN at a glance. J. Cell Sci. 125, 4687–4692.
        Lee J.O. et al. 1999. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell. 99, 323-324.
        Song M.S. et al. 2012. The functions and regulation of the PTEN tumor suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296.  
        Al-Khouri A.M. et al. 2005. Cooperative phosphorylation of the tumor suppressor phosphatase tensin homologye (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 280, 35195-35202.
        Torres J. and Pulido R. 2001. The tumor suppresspr PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276, 993-998.
        Rahdar M. et al. 2009. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc. Natl. Acad. Sci. USA. 106, 480-485.
        Yim E.K. et al. 2009. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell. 15, 304-314.
        Maddika S. et al. 2011. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 13, 728-733.
        Li Z. et al. 2005. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 7, 399-404.
        Trotman L.C. et al. 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 128, 141-156.
        González-Santamaría J. et al. 2012. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis. 3, e393.
        Huang J. et al. 2012. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat. Commun. 3, 911.
        Bassi C. et al. 2013. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science. 341, 395-399.
        Okumura K. et al. 2006. PCAF modulates PTEN activity. J. Biol. Chem. 281, 26562-26568.
        Ikenoue T. et al. 2008. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 68, 6908-6912.
        Cho S.H. et al. 2004. Redox regulation of PTEN and protein tyrosine phosphatases in H2O2-mediated cell signaling. FEBS Lett. 560, 7-13.
        Cao J. et al. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 28, 1505-1517.
        Horita H. et al. 2017. Identifying regulatory posttranslational modifications of PD-L1: A focus on monoubiquitinaton. Neoplasia. 19, 346-353.
        Xu W. et al. 2014. Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Drug Des. Devel. Ther. 8, 1745-1751.